NCT00720499 - Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

141

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

February 28, 2009

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

BI 1744 CL plus tiotropium bromide

BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation

DEVICE

Respimat® Inhaler

Trial Locations (24)

1237.9.00152 Boehringer Ingelheim Investigational Site, Clearwater

1237.9.00155 Boehringer Ingelheim Investigational Site, Tampa

1237.9.00151 Boehringer Ingelheim Investigational Site, Philadelphia

1237.9.00154 Boehringer Ingelheim Investigational Site, Killeen

1237.9.00153 Boehringer Ingelheim Investigational Site, Spokane

1237.9.03253 Boehringer Ingelheim Investigational Site, Brussels

1237.9.03255 Boehringer Ingelheim Investigational Site, Brussels

1237.9.03254 Boehringer Ingelheim Investigational Site, Edegem

1237.9.03251 Boehringer Ingelheim Investigational Site, Ghent

1237.9.03252 Boehringer Ingelheim Investigational Site, Leuven

1237.9.00255 Boehringer Ingelheim Investigational Site, Mississauga

1237.9.00251 Boehringer Ingelheim Investigational Site, Toronto

1237.9.00252 Boehringer Ingelheim Investigational Site, Toronto

1237.9.00254 Boehringer Ingelheim Investigational Site, Toronto

1237.9.00253 Boehringer Ingelheim Investigational Site, Ste-Foy

1237.9.04952 Boehringer Ingelheim Investigational Site, Berlin

1237.9.04953 Boehringer Ingelheim Investigational Site, Berlin

1237.9.04954 Boehringer Ingelheim Investigational Site, Berlin

1237.9.04955 Boehringer Ingelheim Investigational Site, Bruchsal

1237.9.04959 Boehringer Ingelheim Investigational Site, Gelnhausen

1237.9.04960 Boehringer Ingelheim Investigational Site, Großhansdorf

1237.9.04958 Boehringer Ingelheim Investigational Site, Hamburg

1237.9.04951 Boehringer Ingelheim Investigational Site, Tübingen

1237.9.04956 Boehringer Ingelheim Investigational Site, Wiesloch